

Yu Yao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9376528/publications.pdf>

Version: 2024-02-01

50
papers

1,969
citations

331670

21
h-index

265206

42
g-index

50
all docs

50
docs citations

50
times ranked

3124
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive value of TCR V β 2-J β 2 profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial. JCI Insight, 2022, 7, .	5.0	17
2	Comprehensive Next-Generation Sequencing Reveals Novel Predictive Biomarkers of Recurrence and Thoracic Toxicity Risks After Chemoradiation Therapy in Limited Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1165-1176.	0.8	8
3	Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer. Journal of Oncology, 2022, 2022, 1-10.	1.3	1
4	Poor prognosis of intra-tumoural TRBV6-6 variants in EGFR-mutant NSCLC: Results from the ADJUVANT-CTONG1104 trial. Clinical and Translational Medicine, 2022, 12, e775.	4.0	8
5	Somatic Alteration Characteristics of Early-Onset Gastric Cancer. Journal of Oncology, 2022, 2022, 1-11.	1.3	3
6	Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors. Journal of Medical Genetics, 2021, 58, 79-86.	3.2	9
7	Alterations of circulating bacterial DNA in colorectal cancer and adenoma: A proof-of-concept study. Cancer Letters, 2021, 499, 201-208.	7.2	35
8	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 2021, 11, 622648.	2.8	11
9	Timing and Origins of Local and Distant Metastases in Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 1136-1148.	1.1	39
10	Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study. PLoS Medicine, 2021, 18, e1003741.	8.4	60
11	Genomic landscape and evolution of arm aneuploidy in lung adenocarcinoma. Neoplasia, 2021, 23, 870-878.	5.3	3
12	Genomic landscape of metastatic lung adenocarcinomas from large-scale clinical sequencing. Neoplasia, 2021, 23, 1204-1212.	5.3	8
13	Genomic signatures define three subtypes of EGFR-mutant stage III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nature Communications, 2021, 12, 6450.	12.8	48
14	Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nature Communications, 2021, 12, 6770.	12.8	105
15	Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer. Clinical Lung Cancer, 2020, 21, 247-254.	2.6	48
16	Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. Molecular Genetics & Genomic Medicine, 2020, 8, e1079.	1.2	23
17	Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA. Cancer Letters, 2020, 472, 108-118.	7.2	8
18	Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene, 2020, 39, 1846-1859.	5.9	29

#	ARTICLE	IF	CITATIONS
19	Quantitative characterization of tumor cell-free DNA shortening. <i>BMC Genomics</i> , 2020, 21, 473.	2.8	13
20	Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study. <i>ESMO Open</i> , 2020, 5, e000985.	4.5	4
21	Comprehensive next-generation profiling of clonal hematopoiesis in cancer patients using paired tumor-blood sequencing for guiding personalized therapies. <i>Clinical and Translational Medicine</i> , 2020, 10, e222.	4.0	7
22	Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden. <i>Pathology Research and Practice</i> , 2020, 216, 153043.	2.3	21
23	Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 601-611.	3.3	15
24	Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis. <i>Cancer Science</i> , 2020, 111, 2163-2173.	3.9	37
25	Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies. <i>Clinical and Translational Medicine</i> , 2020, 10, e254.	4.0	23
26	Acquired multiple secondary mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a germline mutation. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 612-617.	0.0	18
27	Liquid biopsies using pleural effusion-derived exosomal DNA in advanced lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2019, 8, 392-400.	2.8	24
28	Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy. <i>Journal of Thoracic Oncology</i> , 2019, 14, e85-e88.	1.1	44
29	Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5015-5026.	7.0	143
30	EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 732-736.	1.1	40
31	Widespread and Functional RNA Circularization in Localized Prostate Cancer. <i>Cell</i> , 2019, 176, 831-843.e22.	28.9	317
32	Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI-Treated Non-Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy. <i>Clinical Lung Cancer</i> , 2019, 20, e229-e232.	2.6	5
33	Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 127, 19-24.	2.0	41
34	Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e233-e237.	2.6	11
35	ctDNA as a potential prognostic marker for locally advanced rectal cancer patients with watch and wait approach. <i>Journal of Clinical Oncology</i> , 2019, 37, 3544-3544.	1.6	4
36	Novel genomic prognostic factors for nonsurgical esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy. <i>Journal of Clinical Oncology</i> , 2019, 37, e15589-e15589.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 3097-3107.	7.0	357
38	Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex. <i>Lung Cancer</i> , 2018, 121, 1-4.	2.0	23
39	Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib. <i>Lung Cancer</i> , 2018, 118, 1-5.	2.0	63
40	GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors. <i>Lung Cancer</i> , 2018, 115, 5-11.	2.0	23
41	CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1792-1797.	1.1	29
42	Short-Term Responders of Non-Small Cell Lung Cancer Patients to EGFR Tyrosine Kinase Inhibitors Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms. <i>Translational Oncology</i> , 2018, 11, 1364-1369.	3.7	19
43	Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas. <i>Lung Cancer</i> , 2018, 124, 110-116.	2.0	43
44	Identification of leptomeningeal metastasis-specific exosomal miRNA signature in cerebrospinal fluid of non-small-cell lung cancer patients. <i>Journal of Clinical Oncology</i> , 2018, 36, e21024-e21024.	1.6	2
45	The prevalence of TP53 mutation and primary resistance mechanisms in short-term responders to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, e21237-e21237.	1.6	0
46	Genetic aberrations related to increased risks of brain metastasis in non-small cell lung cancer (GASTO-1036). <i>Journal of Clinical Oncology</i> , 2018, 36, 9092-9092.	1.6	0
47	A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017, 2, e000174.	4.5	3
48	Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types. <i>Scientific Reports</i> , 2017, 7, 583.	3.3	141
49	Cell-Free DNA Provides a Good Representation of the Tumor Genome Despite Its Biased Fragmentation Patterns. <i>PLoS ONE</i> , 2017, 12, e0169231.	2.5	30
50	N-methyl-D-aspartate receptor antagonist MK-801 prevents apoptosis in rats that have undergone fetal spinal cord transplantation following spinal hemisection. <i>Experimental and Therapeutic Medicine</i> , 2014, 8, 1731-1736.	1.8	6